Dr Roxana Mehran (Director of Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine, Mount Sinai Hospital, New York City, NY, USA) kindly shared her thoughts on the the PARADISE-MI trial (NCT02924727) from from the virtual ESC Congress 2021.
Questions
- What has been the impact of angiotensin receptor-neprilysin inhibitors (ARNIs) on the treatment of heart failure, and what unanswered questions remain? (0.13)
- What were the aims and design of the PARADISE-MI trial? (1.43)
- What were the secondary outcomes, and how well were they achieved? (3.23)
- What did you discover about coronary events after acute myocardial infarction? (5.14)
- What do you think will be the focus of research going forward? (8.50)
Speaker disclosures: Dr Roxana Mehran reports institutional research grants from Abbott, Abiomed, Applied Therapeutics, Arena, AstraZeneca, Bayer, Biosensors, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CellAegis, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Insel Gruppe AG, Medtronic, OrbusNeich, Philips; personal fees from ACC, Cine-Med Research, WebMD, SCAI; consulting fees paid to the institution from Abbott, Abiomed, AM-Pharma, Alleviant Medical, Bayer, Beth Israel Deaconess, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, DSI, Duke University, Idorsia Pharmaceuticals, Medtronic, Novartis, Philips; Equity <1% in Applied Therapeutics, Elixir Medical, STEL, CONTROLRAD (spouse); Scientific Advisory Board for AMA, Biosensors (spouse); Faculty CRF (no fee)..
Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.
Filmed during a remote video call with Dr Roxana Mehran as a highlight of ESC 2021, September 2021.
